Harvard Bioscience/$HBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harvard Bioscience
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Ticker
$HBIO
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
343
ISIN
US4169061052
Website
HBIO Metrics
BasicAdvanced
$23M
-
-$1.33
1.45
-
Price and volume
Market cap
$23M
Beta
1.45
52-week high
$3.60
52-week low
$0.28
Average daily volume
24M
Financial strength
Current ratio
0.808
Quick ratio
0.342
Long term debt to equity
48.736
Total debt to equity
242.386
Interest coverage (TTM)
-1.25%
Profitability
EBITDA (TTM)
2.97
Gross margin (TTM)
57.14%
Net profit margin (TTM)
-63.52%
Operating margin (TTM)
-4.44%
Effective tax rate (TTM)
-0.13%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-2.38%
Return on equity (TTM)
-138.80%
Valuation
Price to revenue (TTM)
0.245
Price to book
1.53
Price to tangible book (TTM)
-5.32
Price to free cash flow (TTM)
-110.228
Free cash flow yield (TTM)
-0.91%
Free cash flow per share (TTM)
-0.46%
Growth
Revenue change (TTM)
-14.41%
Earnings per share change (TTM)
550.12%
3-year revenue growth (CAGR)
-8.85%
10-year revenue growth (CAGR)
-1.70%
3-year earnings per share growth (CAGR)
101.42%
10-year earnings per share growth (CAGR)
68.39%
What the Analysts think about HBIO
Analyst ratings (Buy, Hold, Sell) for Harvard Bioscience stock.
HBIO Financial Performance
Revenues and expenses
HBIO Earnings Performance
Company profitability
HBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harvard Bioscience stock?
Harvard Bioscience (HBIO) has a market cap of $23M as of June 27, 2025.
What is the P/E ratio for Harvard Bioscience stock?
The price to earnings (P/E) ratio for Harvard Bioscience (HBIO) stock is 0 as of June 27, 2025.
Does Harvard Bioscience stock pay dividends?
No, Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Harvard Bioscience dividend payment date?
Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Harvard Bioscience?
Harvard Bioscience (HBIO) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.